COMPANY

Vertero Therapeutics

HQ: Woburn, MA source · vertero.com ↗ · New England

Keywords: neurology Parkinson's disease small molecule Parkinsons Disease Parkinson's Disease Autism Spectrum Disorder VT-5006 AB-2004

Location: Woburn, MA · source · Oct 14, 2026

Profile checked Oct 10, 2026

Timeline

Oct 30, 2025 Trial start Phase 1: Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease source ↗
Sep 25, 2025 Trial start —: Research Into the Expression of the csgA-gene and How it Changes in Patients With Parkinson's Disease source ↗
Aug 2, 2021 Trial start Phase 2: AB-2004 in Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) source ↗

Nov 30, 2026 (ESTIMATED) · · Research Into the Expression of the csgA-gene and How it Changes in Patients With Parkinson's Disease · NCT07175922

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT07175922	Research Into the Expression of the csgA-gene and How it Changes in Patients With Parkinson's Disease	Not listed	Recruiting	Sep 25, 2025	Nov 30, 2026 (estimated)
NCT07310264	Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease	Phase 1	Recruiting	Oct 30, 2025	Sep 28, 2026 (estimated)
NCT04895215	AB-2004 in Treatment of Irritability Associated With Autism Spectrum Disorder (ASD)	Phase 2	Completed	Aug 2, 2021	Nov 15, 2023 (actual)